Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
(2016) In The Lancet 387(10020). p.770-778- Abstract
- Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8504580
- author
- organization
- publishing date
- 2016
- type
- Contribution to journal
- publication status
- published
- subject
- in
- The Lancet
- volume
- 387
- issue
- 10020
- pages
- 770 - 778
- publisher
- Elsevier
- external identifiers
-
- pmid:26673811
- scopus:84959074796
- wos:000370418000036
- ISSN
- 1474-547X
- DOI
- 10.1016/S0140-6736(15)00667-4
- language
- English
- LU publication?
- yes
- id
- 510f4b65-b6b9-4a3c-b3ad-77ea36e877ed (old id 8504580)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26673811?dopt=Abstract
- date added to LUP
- 2016-04-04 08:25:34
- date last changed
- 2022-04-23 17:11:05
@article{510f4b65-b6b9-4a3c-b3ad-77ea36e877ed, abstract = {{Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma.}}, author = {{Dreyling, Martin and Jurczak, Wojciech and Jerkeman, Mats and Silva, Rodrigo Santucci and Rusconi, Chiara and Trneny, Marek and Offner, Fritz and Caballero, Dolores and Joao, Cristina and Witzens-Harig, Mathias and Hess, Georg and Bence-Bruckler, Isabelle and Cho, Seok-Goo and Bothos, John and Goldberg, Jenna D and Enny, Christopher and Traina, Shana and Balasubramanian, Sriram and Bandyopadhyay, Nibedita and Sun, Steven and Vermeulen, Jessica and Rizo, Aleksandra and Rule, Simon}}, issn = {{1474-547X}}, language = {{eng}}, number = {{10020}}, pages = {{770--778}}, publisher = {{Elsevier}}, series = {{The Lancet}}, title = {{Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.}}, url = {{http://dx.doi.org/10.1016/S0140-6736(15)00667-4}}, doi = {{10.1016/S0140-6736(15)00667-4}}, volume = {{387}}, year = {{2016}}, }